Companies /Healthcare

Atara Biotherapeutics Inc

NASDAQ: ATRA Biotechnology
$7.70
▼ $0.23 (−2.90%) today
Markets closed · 11:23pm ET

ATRA at a Glance

Valuation
Market cap
$78.5M
Profitability
Revenue (TTM)
$4.0M
EPS (TTM)
$-1.12
Price
52-week range
$4 – $19
Street target
$13.67

Headquartered in Thousand Oaks, CA Fiscal year ends December NASDAQ: ATRA atarabio.com

About Atara Biotherapeutics

Atara Biotherapeutics is a T-cell immunotherapy company that develops off-the-shelf allogeneic cell therapies for difficult-to-treat cancers and autoimmune conditions, delivered to patients from inventory. Its T-cell platform targets Epstein-Barr virus (EBV), the root cause of certain diseases, and does not require T-cell receptor or HLA gene editing. The company's lead product is tabelecleucel (tab-cel, marketed as EBVALLO), an allogeneic EBV-specific T-cell therapy. Atara states it was the first company in the world to receive regulatory approval of an allogeneic T-cell immunotherapy. Tab-cel is under FDA review for EBV+ post-transplant lymphoproliferative disease (PTLD) via a BLA resubmission held by partner Pierre Fabre, with a PDUFA target date of March 31, 2027. Atara earns commercialization revenue under its global partnership with Pierre Fabre. It is eligible for a $31 million milestone on U.S. approval, significant double-digit tiered royalties on net sales, and sales-based milestones. Following extensive cost reductions in 2025 and 2026, the company operates with a minimal expense base and a cash runway into mid-2027. Updated

ATRA Coverage

Frequently Asked Questions

What does Atara Biotherapeutics do?

Atara Biotherapeutics is a T-cell immunotherapy company that develops off-the-shelf allogeneic cell therapies for difficult-to-treat cancers and autoimmune conditions, delivered to patients from inventory.

What is the ATRA stock price target?

The Wall Street consensus 12-month price target for ATRA is $13.67.